Study on the changes of thrombus related factors of spleen-kidney Qi deficiency with blood stasis type diabetic nephropathy

Study on the changes of thrombus related factors of spleen-kidney Qi deficiency with blood stasis type diabetic nephropathy - Study on thrombus factor

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300078580

Enrollment

Unknown

Registered

2023-12-13

Start date

2024-01-01

Completion date

Unknown

Last updated

2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

the changes of thrombus related factors of spleen-kidney Qi deficiency with blood stasis type diabetic nephropathy

Interventions

Healthy control group:NA

NA group:NA

MA group:NA

LA group :NA

Treatment group:Intervention of self-designed decoction for invigorating spleen and invigorating kidney and Promoting blood Circulation

Control group:Routine hypoglycemic, lipid-lowering, dietary, and exercise therapy

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.In accordance with the diagnostic criteria of T2DM and DN, the ACR of early diabetic nephropathy was 2.5-30.0mg/mmol (male) and 3.5-30.0mg/mmol (female). ACR>30.0mg/mmol in clinical diabetic nephropathy group.2.The age range is 18-65.3.Those who did not take any drugs affecting the four indicators of thrombus during the trial.

Exclusion criteria

Exclusion criteria: 1.Non-dn diseases due to other causes ; People with a history of hypertension.2.Patients with severe heart, liver, renal insufficiency, malignant tumor or other serious diseases of various systems.3.DM was complicated with acute complications (ketoacidosis, electrolyte disturbance, infection, hyperosmolar state) and severe chronic complications (diabetic retinopathy greater than or equal to grade 4, diabetic foot).4.Use ACEI or ARB drugs ;Patients who had taken drugs that affected blood clotting indexes, such as aspirin, warfarin, clopidogrel, etc., 2 weeks before the visit.5.GFR was used to assess patients with renal hyperperfusion, transient ACR elevation, and low GFR due to other causes.6.Mental patients and pregnant or lactating women.7.Those who do not sign informed consent.8.Allergic constitution or a history of multiple drug allergies.

Design outcomes

Primary

Measure	Time frame
24-hour urinary microalbumin quantification;Thrombosis four items((TAT,PIC,TM,tPAI·C);Coagulation function indicators(PT,PT-INR,APTT,TT,FIB);	—

Secondary

Measure	Time frame
TC;LDL-C;HDL-C;BMI;	—

Countries

China

Contacts

Public ContactLiu Xiao

Hebei Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine

13013220396@163.com+86 189 3278 8227

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026